IP Library Granted Patent US 8,748,132
Granted Patent B2
US 8,748,132 · App. 13/125,328 · Granted Jun 10, 2014

Process for preparing inclusion body-forming protein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,748,132
App. No.
13/125,328
Granted
Jun 10, 2014
Kind
B2
Abstract

A process for preparing an inclusion body-forming protein is provided. A nucleic acid fragment having a nucleotide sequence coding for a modified alkaline phosphatase signal peptide (modified APSP) where leucine at the 13th position in the amino acid sequence shown in SEQ ID NO: 1 is substituted with proline and/or alanine at the 21st position is substituted with the other amino acid, downstream of which nucleotide sequence is bound a nucleotide sequence of a gene of a protein of interest is also provided.

Claims (22)

1. A nucleic acid fragment consisting of a nucleotide sequence coding for a protein that forms an inclusion body when expressed in prokaryotic cells (inclusion body-forming protein), said fragment comprising a nucleotide sequence coding for a signal peptide and a nucleotide sequence coding for a protein of interest,

wherein the signal peptide consists of the sequence of SEQ ID NO: 1 with:

(i) a substitution of leucine at the 13th position with any one of the amino acids selected from the group consisting of proline, phenylalanine and tryptophan, or

(ii) a substitution of leucine at the 13th position as set forth in (i) and a substitution of alanine at the 21st position with any one of the amino acids selected from the group consisting of aspartic acid, glutamic acid, lysine, histidine, phenylalanine and tyrosine.

2. The nucleic acid fragment of claim 1 wherein said prokaryotic cells are Gram negative bacteria.

3. The nucleic acid fragment of claim 1 wherein said prokaryotic cells are E. coli.

4. The nucleic acid fragment of claim 1 wherein said protein of interest is the pro-matrix metalloprotease 7 (proMMP-7) set forth by SEQ ID NO: 22.

5. The nucleic acid fragment of claim 1 wherein the nucleotide sequence coding for the protein of interest is downstream of the nucleotide sequence coding for the signal peptide.

6. An expression vector comprising the nucleic acid fragment of claim 1 .

7. A host producing an inclusion body-forming protein obtained by transforming a host with the expression vector as set forth in claim 6 .

8. The host producing an inclusion body-forming protein of claim 7 wherein the host is prokaryotic cells.

9. The host producing an inclusion body-forming protein of claim 7 wherein the host is Gram negative bacteria.

10. The host producing an inclusion body-forming protein of claim 7 wherein the host is E. coli.

11. A process for preparing a protein that forms an inclusion body when expressed in prokaryotic cells (an inclusion body-forming protein), the process consisting of (1) to (3):

(1) preparing an expression vector comprising the nucleic acid fragment of claim 1 ,

(2) preparing a host cell transformed with the expression vector of (1) above that produces an inclusion body-forming protein, and

(3) purifying the inclusion body-forming protein from culture obtained by culturing the host cell of (2) above that produces the inclusion body-forming protein.

12. The process of claim 11 wherein said expression vector is an expression vector where the nucleic acid fragment is incorporated downstream of a T7 promoter.

13. The process of claim 11 wherein the host is prokaryotic cells.

14. The process of claim 11 wherein the host is Gram negative bacteria.

15. The process of claim 11 wherein the host is E. coli.

16. The process of claim 11 wherein the host cell that produces the inclusion body-forming protein is cultured in an antibiotic-free culture medium.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2024
From: KM BIOLOGICS CO., LTD.
To: CUREDISC CORPORATION
Reel/Frame 069090/0119 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2024
From: TEIJIN LIMITED
To: CUREDISC CORPORATION
Reel/Frame 069090/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2020
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 051520/0971 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 15, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 050169/0778 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2016
From: TEIJIN PHARMA LIMITED
To: TEIJIN LIMITED
Reel/Frame 040148/0504 →
CORPORATE ADDRESS CHANGE Recorded Jan 16, 2013
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 029637/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2011
From: NAKATAKE, HIROSHI; META, AKIHIRO; SUENAGA, KIYOTAKA; HIRASHIMA, MASAKI; MAEDA, HIROAKI
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE; TEIJIN PHARMA LIMITED
Reel/Frame 026180/0201 →